JPRN-jRCT2051210083招募中1 期
Phase I, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of A Single Intravenous PPMX-T003 in Polycythemia Vera
Ito Tomoki0 个研究点目标入组 6 人开始时间: 2021年9月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old(—)
- 性别
- All
入选标准
- •1. Confirmed diagnosis of PV according to either the 2008 or 2016 WHO classification criteria
- •2. PV patients being only treated with phlebotomy and the interval is 4-9 weeks
排除标准
- •Patients administrated drugs for PV treatment such as hydroxyurea or ruxolitinib (aspirin is excluded)
研究者
相似试验
尚未招募
1 期
First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumorCTRI/2024/07/070802Jubilant Therapeutics India Limited
已完成
1 期
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsJPRN-jRCT2080224901AbbVie G.K.18
已完成
不适用
A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and hematological tumors characterized by wild-type TP53Solid and hematologic tumors1002432410027655NL-OMON46915ovartis24
招募中
1 期
A Study of AZD0486 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaJPRN-jRCT2041230077Misaki Masako9
已完成
不适用
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid TumorsNeoplasmsKCT0004583Abion84
